Results from the AUGMENT 101 trial revealed that more than half of patients with acute leukemias of two types showed a clinical response.
Investigators also reported limited cases of high-grade treatment-related toxicities among patients with advanced acute leukemias with KMT2A rearrangements or NPM1 mutations who received revumenib (SNDX-5613, Syndax Pharmaceuticals) — an oral small-molecule menin inhibitor.
The journal Nature published the latest data along with an additional analysis by another group. This study examines how leukemia cells change.
